MedTrace Logo

Daily Low-level Red Light and 0.01% Low-dose Atropine for Myopia Prevention

NCT06727019 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 138

Last updated 2024-12-10

No results posted yet for this study

Summary

To compare the preventive effects of daily low-level red-light and 0.01% low-dose atropine eye drops on myopia.

Conditions

  • Myopia

Interventions

DEVICE

low-level red-light

650-nm low-level red-light

DRUG

Atropine (0.01%)

Atropine eye drops at concentration of 0.01%

Sponsors & Collaborators

  • Beijing Tongren Hospital

    lead OTHER

Principal Investigators

  • Liya Qiao, PhD · Beijing Tongren Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
7 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-04-10
Primary Completion
2023-09-15
Completion
2023-09-15

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06727019 on ClinicalTrials.gov